134 related articles for article (PubMed ID: 35146482)
21. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
22. Targeted genetics in Drosophila cell lines: Inserting single transgenes in vitro.
Manivannan SN; Simcox A
Fly (Austin); 2016 Jul; 10(3):134-41. PubMed ID: 27261098
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
24. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
25. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
[TBL] [Abstract][Full Text] [Related]
26. Using the GEMM-ESC strategy to study gene function in mouse models.
Huijbers IJ; Del Bravo J; Bin Ali R; Pritchard C; Braumuller TM; van Miltenburg MH; Henneman L; Michalak EM; Berns A; Jonkers J
Nat Protoc; 2015 Nov; 10(11):1755-85. PubMed ID: 26492136
[TBL] [Abstract][Full Text] [Related]
27. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.
Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B
Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464
[TBL] [Abstract][Full Text] [Related]
28. Inducible cassette exchange: a rapid and efficient system enabling conditional gene expression in embryonic stem and primary cells.
Iacovino M; Bosnakovski D; Fey H; Rux D; Bajwa G; Mahen E; Mitanoska A; Xu Z; Kyba M
Stem Cells; 2011 Oct; 29(10):1580-8. PubMed ID: 22039605
[TBL] [Abstract][Full Text] [Related]
29. Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.
Dorris ER; Blackshields G; Sommerville G; Alhashemi M; Dias A; McEneaney V; Smyth P; O'Leary JJ; Sheils O
Cancer Biol Ther; 2016 May; 17(5):526-42. PubMed ID: 26828826
[TBL] [Abstract][Full Text] [Related]
30. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
Loria R; Bon G; Perotti V; Gallo E; Bersani I; Baldassari P; Porru M; Leonetti C; Di Carlo S; Visca P; Brizzi MF; Anichini A; Mortarini R; Falcioni R
Oncotarget; 2015 Feb; 6(5):2779-93. PubMed ID: 25576923
[TBL] [Abstract][Full Text] [Related]
31. Generation of three isogenic gene-edited Huntington's disease human embryonic stem cell lines with DOX-inducible NGN2 expression cassette in the AAVS1 safe locus.
Villegas LD; Chandrasekaran A; Andersen SAF; Nørremølle A; Schmid B; Pouladi MA; Freude K
Stem Cell Res; 2024 Jun; 77():103408. PubMed ID: 38569398
[TBL] [Abstract][Full Text] [Related]
32. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
33. Improvement on the genetic engineering of an invasive agricultural pest insect, the cherry vinegar fly, Drosophila suzukii.
Ahmed HMM; Heese F; Wimmer EA
BMC Genet; 2020 Dec; 21(Suppl 2):139. PubMed ID: 33339511
[TBL] [Abstract][Full Text] [Related]
34. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
Xie X; Koh JY; Price S; White E; Mehnert JM
Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
[TBL] [Abstract][Full Text] [Related]
35. An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes.
Hubner EK; Lechler C; Kohnke-Ertel B; Zmoos AF; Sage J; Schmid RM; Ehmer U
J Gene Med; 2017 Jan; 19(1-2):. PubMed ID: 28009940
[TBL] [Abstract][Full Text] [Related]
36. High-fidelity
Ackermann AM; Zhang J; Heller A; Briker A; Kaestner KH
Mol Metab; 2017 Mar; 6(3):236-244. PubMed ID: 28271030
[TBL] [Abstract][Full Text] [Related]
37. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
38. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract][Full Text] [Related]
39. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
40. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
